The grant encompasses $100,000 each from the Life Sciences Entrepreneurship Center and Berkeley SkyDeck, with SkyDeck having ...

Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

Scientific breakthroughs, operational innovation, and cultural shifts are driving tomorrow’s medicines.

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) ...

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics ...

Pharmaceutical Technology® spoke with Martin Meeson, CEO of Axplora, about the role contract development and manufacturing ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...

Pharmaceutical Compounding Calculations, Part One–Non-Salts, Salts, and Policy-Exception Salts ...

In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, ...

Pharmaceutical Compounding Calculations, Part One–Non-Salts, Salts, and Policy-Exception Salts ...